Strong injectables portfolio to support Aurobindo Pharma's growth

The stock has been underperforming recent months and trades at a discount to peers

A two-fold jump in injectable revenues, commissioning of new facilities and robust product pipeline is expected to help Aurobindo Pharma post double digit revenue growth over the next couple of years. In addition to the topline momentum, plans to demerge the injectables unit could also lead to value unlocking for the shareholders, say analysts.

The stock which has underperformed peers since the start of the year on muted performance in the US injectables segment (down 11 per cent YoY) in December quarter and expectations of near term weakness could see an uptick on multiple triggers and moderate valuations. Among the